Observation of the clinical efficacy of hyperbaric oxygen-assisted Etanercept in the treatment of 40 cases of ankylosing spondylitis
Objective To investigate the clinical efficacy and mechanism of action of hyperbaric oxygen(HBO)-assisted recombinant human type Ⅱ tumor necrosis factor-α(TNF-ot)receptor Fe fusion protein(Etanercept)in the treatment of ankylosing spondylitis(AS).Methods A total of 80 AS patients admitted to the Orthopedics Department of Yantaishan Hospital from January 2019 to December 2020 were selected and randomly divided into study group(n=40)and control group(n=40).The control group was treated with Etanercept on the basisof traditional treatment,while the study group received HBO therapy on the basis of the treatment in the control group.Venous blood samples were collected in the morning before treatment and three months after treatment,and TNF-α levels were measured by enzyme-linked immunosorbent assay(ELISA).The content of C-reactive protein(CRP)was detected by immunoturbidimetry,and the erythrocyte sedimentation rate(ESR)was detected by Westergren method.The changes of peripheral blood B cell subsets were measured by flow cytometry.The results of Bath ankylosing spondylitis functional index(BASFI)and the Bath ankylosing spondylitis disease activity index(BASDAI)were compared between the two groups before and after treatment,and the spinal pain and nocturnal pain in the two groups before and after treatment were evaluated with the Visual Analogue Scale(VAS)before and after treatment.The bone changes before and after treatment were measured by color Doppler ultrasonic diagnostic apparatus.Results The total effective rate of the study group was higher than that of the control group(95.0％vs.80.0％),with a statistically significant difference(x2=4.841,P＜0.05).Compared with the control group after treatment,BASFI and BASDAI scores and VAS score in the study group were significantly reduced after treatment,along with shortened morning stiffness duration,decreased finger-to-floor distance,and increased chest mobility(P＜0.05);Serum CRP,TNF-α,ESR,the percentages of CD19+,CD24int,and CD38int mature B cells,and the percentages of CD19+,CD24hi,and CD38-memory B cells all decreased significantly(P＜0.05).Conclusion HBO-assisted Etanercept therapy can significantly reduce the clinical symptoms of AS,which is mainly achieved by reducing the levels of serum inflammatory factors,improving the immune function of the body,and repairing the damaged bone.
NETL
NSTL
万方数据
